P53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment
P53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment
复制标题
DOI：
10.1002/1097-0142(19940415)73:8
复制
发表时间：
1994-04
期刊：
影响因子：
6.2
通讯作者：
M. Caleffi;M. Teague;Roy A. Jensen;C. Vnencak-Jones;W. Dupont;F. Parl
中科院分区：
文献类型：
--
作者：
M. Caleffi;M. Teague;Roy A. Jensen;C. Vnencak-Jones;W. Dupont;F. Parl
背景越来越多的证据表明，癌症的发展和进展与基因组水平上突变的积累有关。迄今为止，在散发性乳腺癌中已知的最常见的突变基因似乎是肿瘤抑制基因p53。本研究旨在确定原发性乳腺癌中p53基因突变的频率，将p53突变的存在与已确定的临床病理参数（包括雌激素受体（ER）和孕激素受体（PR）状态）相关联，并评估p53突变对患者生存的预后意义。
Background. There is increasing evidence linking development and progression of cancer to an accumulation of mutations at the genomic level. The most frequently mutated gene known to date in sporadic breast cancer appears to be the tumor suppressor gene p53. This study was designed to determine the frequency of p53 gene mutations in primary breast cancer, to correlate the presence of p53 mutations with established clinicopathologic parameters, including the estrogen receptor (ER) and progesterone receptor (PR) status, and to assess the prognostic significance of p53 mutations regarding patient survival.